Related Experiment Video
Updated: May 24, 2026
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Anti-glioma effect and safety of docetaxel-loaded nanoemulsion
Huil Gaoe1, Zhiqing Pang, Shuaiqi Pan
1School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
Abstract:
Docetaxel, an inhibitor of microtubule depolymerization, has been used for many malignancies. Due to its toxicity and the non-selective distribution of its commercial formulation, Taxotere®, new formulations with less toxicity and tumor targeting need to be explored. For its safety and ease of factory scale production, nanoemulsion, was selected to encapsulate docetaxel. The particle size of docetaxel loaded nanoemulsion (DNE) was 72.3 nm, the average zeta potential was -6.38 mV, the encapsulation efficiency was 93.1% and the drug loading capacity was 2.87%. Although DNE presented similar antiproliferation effects on both U87 cells and bEnd.3 cells, its in vivo toxicity was significantly lower than Taxotere®. In vivo fluorescent imaging suggested nanoemulsions loaded with a fluorescent probe could distribute to the brain and accumulate at the glioma site. The pharmacological experiments also confirmed that the DNE could target glioma sites and prolong the median survival time of mice with gliomas. In conclusion, DNE is a new, less toxic, drug formulation that is effective for brain glioma therapy.
Insights
Docetaxel-loaded nanoemulsion (DNE) offers a safer, targeted brain glioma therapy. This novel formulation shows reduced toxicity and effective accumulation at tumor sites, improving survival in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Docetaxel is a microtubule inhibitor used for malignancies but has toxicity and non-specific distribution.
- Current docetaxel formulations like Taxotere® require improved safety and tumor-targeting strategies.
- Nanoemulsions offer a promising platform for drug delivery due to safety and scalability.
Purpose of the Study:
- To develop and evaluate a docetaxel-loaded nanoemulsion (DNE) for improved brain glioma therapy.
- To assess the toxicity, targeting capability, and therapeutic efficacy of DNE compared to Taxotere®.
- To investigate the potential of DNE for enhanced delivery and accumulation at glioma sites.
Main Methods:
- Docetaxel was encapsulated into nanoemulsions, characterized by particle size, zeta potential, encapsulation efficiency, and drug loading.
- In vitro antiproliferation effects were tested on U87 and bEnd.3 cells.
- In vivo toxicity was compared between DNE and Taxotere®.
- In vivo fluorescent imaging and pharmacological experiments were conducted in glioma-bearing mice.
Main Results:
- Docetaxel-loaded nanoemulsion (DNE) exhibited a particle size of 72.3 nm, zeta potential of -6.38 mV, 93.1% encapsulation efficiency, and 2.87% drug loading.
- DNE showed comparable antiproliferation effects to Taxotere® in vitro but significantly lower toxicity in vivo.
- In vivo imaging demonstrated DNE's distribution to the brain and accumulation at glioma sites.
- Pharmacological studies confirmed DNE's glioma targeting and ability to prolong median survival time in mice.
Conclusions:
- Docetaxel-loaded nanoemulsion (DNE) represents a novel, less toxic drug formulation for brain glioma therapy.
- DNE demonstrates effective glioma targeting and improved therapeutic outcomes in preclinical models.
- Nanoemulsion technology offers a viable strategy for enhancing the safety and efficacy of docetaxel in cancer treatment.
